AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22901422
Drug: Daily pin
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pin site care
Trial: 15882256
Drug: AT1R blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT1R blocker (losartan)
Trial: 15882256
Drug: AT1R blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT1R blocker (candesartan)
Trial: 15882256
Drug: AT1R blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT1R blocker treatment
Trial: 10411764
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam preoperatively with sevoflurane
Trial: 25851802
Drug: Aprepitant (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (80 mg for 15-40 kg, 125 mg for 41-65 kg on day 1, 80 mg for days 2-3)
Trial: 17026492
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg/day for 12 weeks
Trial: 15126259
Drug: Chest radiography
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest radiography alone or in combination with sputum cytologic examination
Trial: 11404278
Drug: Alcohol (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (total dose of 256 g)
Trial: 8485531
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (D1) of Tacrine (40 mg/day)
Trial: 8485531
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (D2) of Tacrine (80 mg/day)
Trial: 3315265
Drug: Euphyllin CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin CR (642 mg total daily dose, 1/3 in the morning and 2/3 in the evening, evening dose at 2200 hr)
Trial: 3315265
Drug: Afonilum Retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afonilum Retard (500 mg total daily dose, equal amounts in the morning and evening, evening dose at 2000 hr)
Trial: 27422692
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) - 20 mL bupivacaine/20 mL saline, intraoperative local infiltration
Trial: 16184062
Drug: 0.50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg/kg midazolam
Trial: 16184062
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg midazolam
Trial: 25365612
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg midazolam
Trial: 16184062
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (1.0 mg/kg midazolam)
Trial: 12626890
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor (PI) users
Trial: 12626890
Drug: Reverse transcriptase
RxNorm normalized name: Reverse transcriptase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reverse transcriptase inhibitor (RTI) users
Trial: 12626890
Drug: No antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiretroviral therapy (ART) users
Trial: 9295498
Drug: Multi-agent controlling
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-agent controlling method to promote milk secretion
Trial: 1852848
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment program (parent training and training of boys for social skills, fantasy play, and television viewing)
Trial: 22349746
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol 15 mg/kg
Trial: 21296248
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol 1.0 mg/kg
Trial: 19577902
Drug: Intranasal packing
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal packing with septal splints and antibiotic meshes
Trial: 17074346
Drug: Oral E(2)
RxNorm normalized name: Aquasol E Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E(2) (oE(2), 1 mg/d)
Trial: 17074346
Drug: Transdermal E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal E(2) (tE(2), 0.05 mg/d)
Trial: 3661439
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg once or twice daily for 6 weeks
Trial: 3661439
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg plus amiloride 2.5 mg once or twice daily for 6 weeks
Trial: 3661439
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg plus hydrochlorothiazide 25 mg and amiloride 2.5 mg
Trial: 3661439
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-dose nisoldipine and low-dose diuretic
Trial: 28103616
Drug: l-Lysine (4.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Lysine (4.95 g/day orally)
Trial: 25742208
Drug: Naltrexone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking
Trial: 25742208
Drug: Daily/targeted placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily/targeted placebo
Trial: 21234852
Drug: Prednisone (Cor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (Cor, 50 mg/day for 7 days)
Trial: 18259123
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (titrated to 100 mg/d at 4 weeks)
Trial: 18259123
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 50 mg (titrated to 100 mg/d at 4 weeks)
Trial: 16907691
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment (efficacy data from RCT)
Trial: 14570732
Drug: Cluster analysis
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster analysis based on rectal sensitivity and psychological symptoms
Trial: 1347230
Drug: H1- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1- and H2-receptor antagonists + Atracurium 0.6 mg kg‐1
Trial: 4007349
Drug: Digoxin therapy
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin therapy (Group A)
Trial: 17014513
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (Group B)
Trial: 24678758
Drug: Manual orthopaedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual orthopaedic therapy with proprioception training
Trial: 17666597
Drug: IVIG 2
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 2 g/kg/wk (group A)
Trial: 17666597
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg/wk plus prednisone 0.5 mg/kg/d (group B)
Trial: 11823672
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL (100 mg once daily)
Trial: 9935096
Drug: LPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPA therapy at 20 J/cm2, double pulsed at a repetition rate of one Hz
Trial: 9935096
Drug: LPA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPA therapy at 20 J/cm2, single pulsed with a pulse duration of 5 msec followed by 23.4% hypertonic saline sclerotherapy
Trial: 8785378
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg selegiline tablet
Trial: 8785378
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg selegiline solution
Trial: 8785378
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both dosage forms
Trial: 8785378
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (tablet and solution)
Trial: 27999018
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (0.3‐0.6 mg/kg twice daily) with ART (tenofovir, emtricitabine and lopinavir/ritonavir) for 8 weeks
Trial: 23263720
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a plus ribavirin (135‐180 µg subcutaneously/week and 800‐1200 mg/day orally)
Trial: 23263720
Drug: interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interferon alfa‐2b plus ribavirin (300‐500 million units, once every other day and 800‐1200 mg/day)
Trial: 14719195
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every other week
Trial: 15146409
Drug: Adalimumab 20
RxNorm normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 20 mg subcutaneously every week
Trial: 10467196
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg twice daily, n = 14)
Trial: 7601400
Drug: Bolus somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus somatostatin (250 micrograms injection followed by 250 micrograms/h infusion)
Trial: 7601400
Drug: Continuous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous somatostatin (250 micrograms/h infusion)
Trial: 7601400
Drug: Continuous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous somatostatin (500 micrograms/h infusion)
Trial: 2210972
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg at 12-hour intervals (30 subjects)
Trial: 2210972
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg at 12-hour intervals (24 subjects)
Trial: 2210972
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg at 12-hour intervals for three days (23 subjects with uncomplicated UTI)
Trial: 31331065
Drug: Partially hydrolysed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolysed whey formula with 1.8 g protein/100 kcal (pHF1.8)
Trial: 31331065
Drug: Partially hydrolysed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolysed whey formula with 2.27 g protein/100 kcal (pHF2.27)
Trial: 31331065
Drug: Partially hydrolysed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolysed whey formula with 2.0 g protein/100 kcal (pHF2.0)
Trial: 28698351
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intranasal ketamine
Trial: 28698351
Drug: Volume-matched intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-matched intranasal normal saline (placebo)
Trial: 28698351
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic therapy (for all participants)
Trial: 23807349
Drug: Brimonidine-timolol fixed
RxNorm normalized name: brimonidine / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine-timolol fixed combination therapy (FCBT)
Trial: 23807349
Drug: Dorzolamide-timolol fixed
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol fixed combination therapy (FCDT)
Trial: 19523908
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (0.1 ml of trivalent inactivated influenza vaccine, 3 microg of hemagglutinin per strain)
Trial: 19523908
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (0.25 ml of trivalent inactivated influenza vaccine, 7.5 microg of hemagglutinin per strain)
Trial: 8070610
Drug: Lisinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-20 mg/day)
Trial: 27864832
Drug: Colistin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (2.5 million IU intravenous dose)
Trial: 21791965
Drug: hm gamma-PGA
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hm gamma-PGA treatment in rats (NFP or HFP) for 4 weeks
Trial: 21791965
Drug: hm gamma-PGA
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hm gamma-PGA supplementation (150 mg/day) in humans for 8 weeks
Trial: 19332187
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months clopidogrel therapy after DES implantation
Trial: 19332187
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months clopidogrel therapy after DES implantation
Trial: 15190231
Drug: SR 142801
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 142801 (NK3 receptor antagonist)
Trial: 15190231
Drug: SR 48692
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48692 (neurotensin receptor antagonist)
Trial: 15190231
Drug: SR 141716
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 141716 (cannabinoid receptor antagonist)
Trial: 2871849
Drug: Atracurium (0.135-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.135-0.5 mg kg‐1)
Trial: 2871849
Drug: Vecuronium (0.02-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.02-0.1 mg kg‐1)
Trial: 2871849
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of equipotent doses of atracurium and vecuronium
Trial: 31210635
Drug: Sound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound therapy (maskers)
Trial: 31210635
Drug: No sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sound therapy (control)
Trial: 22711499
Drug: 238 g
RxNorm normalized name: AVOBENZONE 3.371 g in 112.38 g / OXYBENZONE 6.743 g in 112.38 g / OCTINOXATE 8.429 g in 112.38 g / HOMOSALATE 11.238 g in 112.38 g / OCTISALATE 5.619 g in 112.38 g TOPICAL CREAM [Advanced Sun Resistance SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 238 g PEG + 1.9 L Gatorade
Trial: 22711499
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of PEG-ELS
Trial: 18721566
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) kallikrein inhibiting units (KIU) loading dose, 0.5 x 10(6) KIU/hour)
Trial: 11954952
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no colforsin treatment)
Trial: 10623332
Drug: Nebuhaler pressurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler pressurized metered dose inhaler (pMDI)
Trial: 7494824
Drug: Pure water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure water (control solution)
Trial: 7494824
Drug: Mannitol 10
RxNorm normalized name: mannitol 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 10 g/200 ml
Trial: 2188794
Drug: Eicosapentaenoic acid-rich
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid-rich fish oil (MaxEPA', 2.8 g EPA daily)
Trial: 7003448
Drug: 0.96 g
RxNorm normalized name: TRIHEPTANOIN 0.96 g in 1 mL ORAL LIQUID [DOJOLVI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.96 g single oral dose of co-trimoxazole
Trial: 7003448
Drug: 1.92 g
RxNorm normalized name: STARCH, CORN 31.92 g in 100 g TOPICAL PATCH [Legere Lavendar Foot Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.92 g single oral dose of co-trimoxazole
Trial: 7003448
Drug: 2.88 g
RxNorm normalized name: ALCOHOL 2.16 g in 2.88 g / BENZALKONIUM CHLORIDE 0.003 g in 2.88 g TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.88 g single oral dose of co-trimoxazole
Trial: 27298538
Drug: Sub-mucosal injection
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-mucosal injection of 0.5 mg/kg ketamine hydrochloride
Trial: 24632042
Drug: EG 500
RxNorm normalized name: Prosys Leg 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG 500 (500 mg of encapsulated C. xanthocarpa)
Trial: 24632042
Drug: EG 1000
RxNorm normalized name: BAG,LEG 1000ML CARDINAL #ZRLB1000H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG 1000 (1000 mg of encapsulated C. xanthocarpa)
Trial: 24632042
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG, placebo treatment)
Trial: 15155114
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 microg subcutaneous daily)
Trial: 11369904
Drug: BCX-34 dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCX-34 dermal cream 1%
Trial: 8214490
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (0.027 mg)
Trial: 8214490
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (0.027 mg)
Trial: 28124444
Drug: Cognitive-behavioral intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral intervention (CBT) combined with treatment-as-usual (TAU), weekly sessions for 3 months
Trial: 22452928
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure (14, 220, or 354 μg/m3 for 3 hours)
Trial: 16223392
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 2 ml with epinephrine (5 microg/ml)
Trial: 16223392
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 ml with epinephrine (2.5 microg/ml)
Trial: 16223392
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 ml with epinephrine (5 microg/ml)
Trial: 16223392
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine 4 ml (no epinephrine)
Trial: 12139219
Drug: Dengue tetravalent
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue tetravalent live-attenuated vaccine (two doses, given six months apart)
Trial: 10557952
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral prednisone
Trial: 8824656
Drug: 5‐ASA 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA 1.5 g b.d.
Trial: 2285294
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cephradine every 12 h for 7 days
Trial: 2285294
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of amoxicillin‐clavulanate every 8 h for 7 days
Trial: 7041936
Drug: Buprenorphine 1
RxNorm normalized name: buprenorphine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 1 mg + Paracetamol 1000 mg
Trial: 7041936
Drug: Buprenorphine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 1.5 mg + Paracetamol 1000 mg
Trial: 7041936
Drug: Buprenorphine 2
RxNorm normalized name: buprenorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 2 mg + Paracetamol 1000 mg
Trial: 28291545
Drug: Bevacizumab (B)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (B) + single agent chemotherapy (CT)
Trial: 28291545
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent chemotherapy (CT)
Trial: 25565364
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of 0.5 mg dutasteride and 0.4 mg tamsulosin